Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah A Thomas

Showing results (31-40 of 109) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemiaFrancis J Giles, Jorge E Cortes, Deborah A Thomas, et al.
Cancer|March 17, 2004
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimenMary Ann Weiser, Maria E Cabanillas, Marina Konopleva, et al.
British Journal of Haematology|March 8, 2007
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictorsGautam Borthakur, Susan O'Brien, William G Wierda, et al.
Blood|April 16, 2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaConstantine S Tam, Susan O'Brien, William Wierda, et al.
Leukemia & Lymphoma|August 14, 2013
CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysisWenli Zheng, L Jeffrey Medeiros, Ken H Young, et al.
Blood|January 10, 2009
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseConstantine S Tam, Lynne V Abruzzo, Katherine I Lin, et al.
Blood|December 17, 2009
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosisFabio P S Santos, Hagop M Kantarjian, Nitin Jain, et al.
Cancer|October 21, 2010
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromeElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Haematologica|December 31, 2011
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?Guilin Tang, Zhuang Zuo, Deborah A Thomas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 25, 2013
Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphomaYi Zhou, Xiangshan Fan, Mark Routbort, et al.
Pageof 11

Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemiaFrancis J Giles, Jorge E Cortes, Deborah A Thomas, et al.
Cancer|March 17, 2004
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimenMary Ann Weiser, Maria E Cabanillas, Marina Konopleva, et al.
British Journal of Haematology|March 8, 2007
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictorsGautam Borthakur, Susan O'Brien, William G Wierda, et al.
Blood|April 16, 2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaConstantine S Tam, Susan O'Brien, William Wierda, et al.
Leukemia & Lymphoma|August 14, 2013
CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysisWenli Zheng, L Jeffrey Medeiros, Ken H Young, et al.
Blood|January 10, 2009
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseConstantine S Tam, Lynne V Abruzzo, Katherine I Lin, et al.
Blood|December 17, 2009
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosisFabio P S Santos, Hagop M Kantarjian, Nitin Jain, et al.
Cancer|October 21, 2010
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromeElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Haematologica|December 31, 2011
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?Guilin Tang, Zhuang Zuo, Deborah A Thomas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 25, 2013
Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphomaYi Zhou, Xiangshan Fan, Mark Routbort, et al.
Pageof 11